

RESEARCH ARTICLE

LC-ESI/MS/MS analysis of neonicotinoids in urine of very low birth weight infants at birth

Go Ichikawa¹*, Ryota Kuribayashi¹, Yoshinori Ikenaka^{2,3}, Takahiro Ichise², Shouta M. M. Nakayama², Mayumi Ishizuka², Kumiko Taira⁴, Kazutoshi Fujioka⁵, Toshimi Sairenchi⁶, Gen Kobashi⁶, Jean-Marc Bonmatin⁷, Shigemi Yoshihara¹

1 Department of Pediatrics, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan, **2** Laboratory of Toxicology, Department of Environmental Veterinary Sciences, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, **3** Water Research Group, Unit for Environmental Sciences and Management, North-West University, Potchefstroom, North West, South Africa, **4** Department of Anesthesiology, Tokyo Women's Medical University Medical Center East, Arakawa-ku, Tokyo, Japan, **5** Albany College of Pharmacy and Health Sciences, Albany, New York, United States of America, **6** Department of Public Health, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan, **7** Centre National de la Recherche Scientifique, Centre de Biophysique moléculaire, Orléans, France

* These authors contributed equally to this work.

* go-i@zk9.so-net.ne.jp



OPEN ACCESS

Citation: Ichikawa G, Kuribayashi R, Ikenaka Y, Ichise T, Nakayama SMM, Ishizuka M, et al. (2019) LC-ESI/MS/MS analysis of neonicotinoids in urine of very low birth weight infants at birth. PLoS ONE 14(7): e0219208. <https://doi.org/10.1371/journal.pone.0219208>

Editor: Yael Abreu-Villaça, Universidade do Estado do Rio de Janeiro, BRAZIL

Received: March 28, 2019

Accepted: June 18, 2019

Published: July 1, 2019

Copyright: © 2019 Ichikawa et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript.

Funding: This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan awarded to Y. Ikenaka (Nos. 17K2003807 and 18H0413208), and K. Taira (No.15K00559) (www.mext.go.jp). We also acknowledge financial support from Triodos Foundation and act beyond trust (<http://www.triodosfoundation.nl>). The study was supported by

Abstract

Objectives

Neonicotinoid insecticides are widely used systemic pesticides with nicotinic acetylcholine receptor agonist activity that are a concern as environmental pollutants. Neonicotinoids in humans and the environment have been widely reported, but few studies have examined their presence in fetuses and newborns. The objective of this study is to determine exposure to neonicotinoids and metabolites in very low birth weight (VLBW) infants.

Methods

An analytical method for seven neonicotinoids and one neonicotinoid metabolite, *N*-desmethylacetamiprid (DMAP), in human urine using LC-ESI/MS/MS was developed. This method was used for analysis of 57 urine samples collected within 48 hours after birth from VLBW infants of gestational age 23–34 weeks (male/female = 36/21, small for gestational age (SGA)/appropriate gestational age (AGA) = 6/51) who were admitted to the neonatal intensive care unit of Dokkyo Hospital from January 2009 to December 2010. Sixty-five samples collected on postnatal day 14 (M/F = 37/22, SGA/AGA = 7/52) were also analyzed.

Results

DMAP, a metabolite of acetamiprid, was detected in 14 urine samples collected at birth (24.6%, median level 0.048 ppb) and in 7 samples collected on postnatal day 14 (11.9%, median level 0.09 ppb). The urinary DMAP detection rate and level were higher in SGA than in AGA infants (both $p < 0.05$). There were no correlations between the DMAP level and infant physique indexes (length, height, and head circumference SD scores).

JST/JICA, SATREPS (Science and Technology Research Partnership for Sustainable Development)(<https://www.jst.go.jp/global/>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Conclusion

These results provide the first evidence worldwide of neonicotinoid exposure in newborn babies in the early phase after birth. The findings suggest a need to examine potential neurodevelopmental toxicity of neonicotinoids and metabolites in human fetuses.

Introduction

Neonicotinoid insecticides (neonicotinoids) are neurotoxicants with nicotinic acetylcholine receptor (nAChR) modulator action [1–3]. Neonicotinoids were first introduced on the market in the mid-1990s, and now are the most widely used class of insecticides worldwide, both for seed dressings of crops (e.g. maize, oil-seed rape, cotton, and soybeans) and for spraying on rice paddies, fruits, vegetables, tea leaves, cocoa, and coffee beans [3, 4]. In Japan, seven neonicotinoids were registered as pesticides up to 2002, with 70.3 tons of imidacloprid, 53.8 tons of acetamiprid, 8.0 tons of nitenpyram, 21.4 tons of thiacloprid, 34.4 tons of thiamethoxam, 64.2 tons of clothianidin, and 156.8 tons of dinotefuran shipped in 2009 [5,6]. Three more insecticides with nAChR modulator action have recently been registered: flupyra-difurone in 2015, and sulfoxaflor and triflumezopyrim in 2018 [7]. These three molecules are also considered to be neonicotinoids because of their similarity in molecular structure and neuronal effects to those of the original seven neonicotinoids [8].

Since the mid-2000s, many studies have shown that neonicotinoids may have negative effects on non-targeted invertebrates, in particular on honeybees and bumblebees [1,4,8,9–13]. This evidence has led to prohibition of outside use of three neonicotinoids, imidacloprid, clothianidin and thiamethoxam, in the EU since 2013 [14–17] and a total ban on outside use of imidacloprid, clothianidin, thiamethoxam, thiacloprid, and acetamiprid in France in 2019 [18].

Neonicotinoids may also have negative effects on vertebrates [13, 19], including wild birds [20], bats [21], and white-tailed deer [22]. Recent *in vitro* studies have revealed multiple toxicity of neonicotinoids at a low dose, including neurotoxicity of imidacloprid at 0.77 mg/L [23], immunotoxicity of clothianidin at 0.1 mg/L [24], endocrine toxicity of imidacloprid at 0.03 mg/L and thiacloprid at 0.08 mg/L [25], and genotoxicity caused by oxidative stress [26]. A few *in vivo* studies have shown neurodevelopmental toxicity in rodents by imidacloprid 0.5 mg/kg/day, and acetamiprid 1 mg/kg/day, and neurotoxicity with clothianidin 10 mg/kg/day [27–29]. These levels are the same or lower than the no-observed-adverse-effect levels (NOAELs) of 5.7 mg/kg/day for imidacloprid, 7.1 mg/kg/day for acetamiprid, and 9.7 mg/kg/day for clothianidin [30–32]. Several reports suggest that subacute and chronic exposure to neonicotinoids such as acetamiprid and thiamethoxam may be toxic in humans [33,34], and acute high dose exposure of imidacloprid [35], acetamiprid [36, 37], and thiacloprid [38,39] can be lethal. Neonicotinoids are well absorbed by humans after oral intake and are mainly excreted in urine [40–42]. These molecules cross the human blood brain barrier [43], and some neonicotinoids have toxic metabolites, such as desnitroimidacloprid, which has a mammalian nAChR agonistic activity that is as high as that of nicotine [44].

Current reports of neonicotinoid food contamination at less than the maximum residual dose are increasing. Japanese non-organic green tea leaves are contaminated by dinotefuran with imidacloprid, acetamiprid, clothianidin, thiacloprid and thiamethoxam [45]. In the EU, acetamiprid was detected in 10% of apples, imidacloprid in 15.8% of lettuces, and thiacloprid in 11.4% of strawberries [46]. In the US, acetamiprid was detected in 13.4% of fruits and

imidacloprid in 19.9% of vegetables in 1999–2015 [47]. A particularly toxic neonicotinoid metabolite, desnitro-imidacloprid, has been detected in drinking water in the US [48]. Unlike most other pesticides, neonicotinoids cannot be washed off food prior to consumption due to the characteristics of the plant [47].

Frequent detection of neonicotinoids and their metabolites in urine and hair have been reported for the general population [42,49–52], but this has not been investigated in fetuses and newborn babies, despite their potentially high sensitivity to these chemicals [53]. Developing cerebral vessels in infants are more fragile than those in adults and more vulnerable to drugs, toxins, and pathological conditions, which may cause cerebral damage and subsequent neurological disorders [54]. Many adult functions, including effective tight junctions, are not developed in the embryonic brain and some transporters are more active during development than in adults [55,56].

In Japan in 2009, the incidence of low-birth-weight (LBW) infants (<2500 g at birth) was 9.6%, and that of very (V)LBW infants (<1500 g) was 0.74% [57]. LBW infants are classified as small for gestational age (SGA), indicating those who are smaller in size, with weight below the 10th percentile for gestational age; or appropriate for gestational age (AGA), for those who are appropriate in size, with weight and head circumference in the range from the 10th to 90th percentile. In general, neurological development in SGA infants is worse than that in AGA infants [58]. In addition to body weight, head circumference is used as an index of development, and the head circumference SD score can be calculated by the lambda-mu-sigma method using LMS chart-maker. This score is the international standard for newborn size for each gestational age based on data from the Newborn Cross-Sectional Study, which conforms at the population and individual levels to the prescriptive approach used in the WHO Multicentre Growth Reference Study [59]. A low head circumference SD score is related to neurodevelopment delay [58].

In this study, we developed an analytical method for seven neonicotinoids and one neonicotinoid metabolite in human urine. Then we explored exposure to neonicotinoids and metabolites in VLBW infants born in 2009–2010 in the early stage after birth to examine whether neonicotinoids can be transferred to fetuses. These infants are not usually fed with milk for 48 hours at birth. The relationships of detection of neonicotinoids with body weight and head circumference SD scores were also examined.

Subjects and methods

Subjects and sample collection

The subjects were infants born at a gestational age of 23 to 32 weeks and a birth weight of 500–1,500 g who were admitted to the NICU of Dokkyo Medical University Hospital from January 2009 to December 2010. Infants with chromosomal abnormalities, external deformities and life-threatening diseases were excluded. After obtaining approval from the ethics committee of Dokkyo Medical University (approval no. 25042) and informed consent from the infants' parents, urine samples were collected on postnatal days (PNDs) 1 to 2 (within 48 h after birth) and PND 14 using cotton balls or a urine sampling bag, and the samples were stored at -80°C. The cotton ball was applied to the absorbent core in the diaper and collected after it was immersed in urine. The current study was performed using urine samples collected from these infants for a previous study. We obtained new approval from the ethics committee of Dokkyo Medical University (approval no.29008) and gave an explanation to the infants' parents by posting a notice and through an opt-out method, which was also approved by the ethics committee of Dokkyo Medical University.

Chemicals

Acetamiprid, dinotefuran, imidacloprid, nitenpyram and thiacloprid were purchased from Kanto Chemical Corp. (Tokyo, Japan). Clothianidin, clothianidin-d₃, dinotefuran-d₃, imidacloprid-d₄, thiacloprid-d₄, thiamethoxam-d₄, and *N*-desmethylacetamiprid (DMAP) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hydroxyimidacloprid was purchased from Hypha Discovery (Slough, UK). Acetamiprid-d₆ and nitenpyram-d₃ were purchased from Hayashi Pure Chemical Ind. (Osaka, Japan). Thiamethoxam was purchased from Dr. Ehrenstorfer. Acetonitrile, dichloromethane formic acid, ammonium acetate and distilled water were all HPLC grade and were purchased from Kanto Chemical.

Urine sample preparation and analysis. Urine was thawed, stirred, and allowed to stand for some time and the supernatant was used. Purification of urine was performed by solid phase extraction (SPE). A volume of 100 μ L of internal standard mixture (each 10 ppb) was added to 100 μ L of each urine sample, and then 2800 μ L of distilled water was added to the sample. Two types of SPE cartridges were used for purification: an InertSep Pharma SPE column (60 mg/3 ml) (GL Science, Tokyo, Japan) pre-conditioned with 3 mL of an acetonitrile/dichloromethane (1/1) mixture followed by 3 ml of distilled water; and an InertSep PSA SPE column (100 mg/1ml) (GL Science) pre-conditioned with 1 mL of the acetonitrile/dichloromethane (1/1) mixture. Prepared samples were loaded on the pre-conditioned InertSep Pharma and washed with 0.5 mL of distilled water. The InertSep Pharma (top) was combined with the InertSep PSA (bottom) and 3 ml of the acetonitrile/dichloromethane (1/1) mixture were used to elute the target chemicals. After concentrating and dry-solidifying with a centrifugal concentrator (CVE-200D with UT-2000, EYELA, Tokyo, Japan), the samples were reconstituted with 100 μ L of 3% methanol in distilled water and transferred to vials for analysis. Seven neonicotinoids and DMAP were analyzed in each sample. Recovery rates and LOQs are shown in [Table 1](#).

A LC-ESI/MS/MS system (Agilent 6495B, Agilent Technologies, Santa Clara, CA, USA) equipped with a Kinetex Biphenyl column (2.1 mm ID \times 100 mm, ϕ 2.6 μ m, Phenomenex, Torrance, CA, USA) was used for sample analysis. Solvents A and B used for HPLC analysis were 0.1% formic acid + 10 mM ammonium acetate in aqueous solution and 0.1% formic acid + 10 mM ammonium acetate in methanol, respectively. The gradient was programmed as: $t = 0$ to 1 min: 5% B, $t = 6$ min: 95% B, $t = 6$ to 8 min: 95% B. The column oven temperature and flow rate were 60 °C and 0.5 ml/min, respectively. For mass spectrometry, multiple reaction monitoring (MRM) was programmed ([Table 1](#)). The recovery rate of each neonicotinoid and its metabolites ranged from 80% (acetamiprid) to 117% (thiamethoxam). The reproducibility of the analysis system was confirmed in the same or plural analyses, with a relative standard deviation (RSD) of 10% for all the compounds.

Quantitation of neonicotinoids and their metabolites. Seven neonicotinoids and DMAP ([Table 1](#)) were analyzed in each sample. Six compounds were used as internal standards. The precursor and product ions are shown in [Table 1](#). Quantification of the neonicotinoids and metabolites was carried out by the internal standard method. Five calibration points were set at 0.5, 1.25, 2.5, 3.75 and 5 ppb, whereas the internal standard was used to 5 ppb at all calibration points.

Quality control and quality assurance. A mixture of six deuterium-labeled neonicotinoids was spiked into samples as an internal standard prior to sample preparation and extraction. Quantitation was performed using five calibration points and the average coefficients of determination (r^2) for the calibration curves were ≥ 0.995 . The analytical method was checked for precision and accuracy. Limits of detection (LODs) were calculated based on $3SD/S$ (SD is the standard deviation of the response of seven replicate standard solution measurements and

Table 1. Properties of target neonicotinoids and metabolites.

Neonicotinoids	MRM ^a (<i>m/z</i>)	RT ^b (min)	Recovery rate (%)	LOQ ^c (ng/ml)
Dinotefuran	203.00>129.10	8.2	92.6 ±2.8	0.125
Nitenpyram	271.00>126.05	8.9	88.6 ±4.6	0.5
Thiamethoxam	291.90>211.00	14.0	116.7 ±7.9	0.125
<i>N</i> -Desmethylacetamiprid (DMAP)	208.90>126.05	15.2	87.6 ±5.4	0.05
Clothianidin	249.90>132.05	16.1	91.8 ±3.7	0.125
Acetamiprid	223.00>126.00	16.2	80.2 ±2.9	0.05
Imidacloprid	256.00>209.05	17.3	87.0 ±2.7	0.5
Thiacloprid	252.90>126.05	19.1	92.9 ±1.8	0.05

^aMRM: multiple reaction monitoring;

^bRT: Retention time;

^cLOQ: limit of quantification

<https://doi.org/10.1371/journal.pone.0219208.t001>

S is the slope of the calibration curve). Recovery rates and LOQs (ng/mL) of the analytes are given in Table 1.

Statistical analysis

IBM SPSS Statistics 23 was used for statistical analysis. A Fisher exact test was used to compare the DMAP detection rates. A Wilcoxon rank sum test for non-parametric data was used to compare DMAP concentrations. Spearman rank correlation coefficient analysis was used to compare the DMAP level and infant physique index (length SD score, height SD score, and head circumference SD score). The significance level was set at $P = 0.05$.

Results

Fourteen of the 130 urine samples collected from 65 subjects could not be analyzed due to insufficient volume, and thus, the final analysis included 116 samples: 57 collected on PND 1–2 (within 48 h after birth) and 59 on PND 14. The background of the subjects, including physical status, is shown in Table 2.

Table 2. Characteristics of infants on postnatal days (PND) 1–2 and 14.

Item	PND 1–2	PND 14	P
Number of samples	57	59	
Gestational age (weeks)	27 (28, 23–34)	27 (28, 23–34)	0.84
Sex, male	36 (63%)	37 (63%)	0.92
Birth weight (g)	1012 (982,515–1474)	967 (926,515–1474)	0.69
Birth weight SD score	-0.6 (-0.6,-3.1–2.0)	-0.6 (0.1,-3.3–2.0)	0.75
Birth length (cm)	35.1 (35, 28–41)	34.7 (35, 28–41)	0.99
Birth length SD score	-0.4 (-0.4,-2.6–1.7)	-0.4 (-0.4,-2.6–1.7)	0.77
Head circumference (cm)	25.3 (25.5,19.8–29.5)	25.0 (24.5,19.8–29.5)	0.89
Head circumference SD score	0.1 (0.2,-1.8–1.4)	0.1(0.3,-1.8–1.4)	0.88
Small for gestational age	6 (11%)	8 (14%)	0.32
Apgar score 5 min	7.6 (8, 1–10)	7.5(7, 1–10)	0.75
Cesarean section	35 (61%)	38 (64%)	0.51

Data are shown as a mean (median, range) or as n (%)

<https://doi.org/10.1371/journal.pone.0219208.t002>

Table 3. Detection of DMAP in urine of VLBW infants on postnatal days (PND) 1–2 and 14.

Item	PND 1–2	PND 14	p
Detection rate (%) (number of samples)	24.6 (14/57)	11.9 (7/59)	0.09
Mean concentration (ppb) (median, range)	0.11 (0.048, 0.01–0.68)	0.13 (0.09, 0.01–0.47)	0.09

<https://doi.org/10.1371/journal.pone.0219208.t003>

Table 4. Differences in detection rates and levels of DMAP in SGA and AGA infants.

Item	SGA ^a	AGA ^b	p
Detection rate (%) (number of samples)	42.9 (6/14)	14.7 (15/102)	0.005
Mean concentration (ppb) (median, range)	0.04 (0, 0–0.3)	0.02 (0, 0–0.68)	0.004

^aSGA: small for gestational age;

^bAGA: appropriate for gestational age

<https://doi.org/10.1371/journal.pone.0219208.t004>

Table 5. Relationships of detection of DMAP on PND 1–2 and head circumference SD score.

Item	Head circumference SD score		p
	Positive	Negative	
Detection rate (%) (number of samples)	16.7 (6/36)	38.1 (8/21)	0.07 *
Mean concentration (ppb) (median, range)	0.025 (0, 0–0.68)	0.032 (0, 0–0.30)	0.07†

*p by χ^2 test.

†p by Wilcoxon rank sum test.

<https://doi.org/10.1371/journal.pone.0219208.t005>

Dinotefuran was detected in one sample and one of the 20 neonicotinoid metabolites, DMAP, was also detected. The concentration of dinotefuran was 0.4 ppb (PND 1–2). DMAP was detected in 14/57 PND 1–2 samples (24.6%) (median level 0.048 ppb, range: 0.01–0.68 ppb), and in 7/59 PND 14 samples (11.9%) (median level 0.09 ppb, range: 0.01–0.47 ppb), with no significant difference in the detection rate ($p = 0.09$) or level ($p = 0.09$) between PND 1–2 and PND 14 samples (Table 3).

The DMAP detection rate was significantly higher in SGA infants than in AGA infants (42.9% vs. 14.7%, $p < 0.05$). The mean DMAP level was similarly significantly higher in SGA infants (0.04 vs. 0.02 ppb, $p < 0.05$) (Table 4). There was no significant difference in DMAP detection rates on PND 1–2 for infants with positive or negative head circumference SD scores ($p = 0.07$) (Table 5). In infants in whom DMAP was detected on PND 1–2, there were weak negative correlations between DMAP levels and birth weight SD scores ($\rho = -0.37$, $p = 0.19$), birth length SD scores ($\rho = -0.36$, $p = 0.20$), and birth head circumference SD scores ($\rho = -0.23$, $p = 0.43$), but none of these relationships were significant.

Discussion

This is the first report worldwide to suggest that DMAP, a toxic metabolite of acetaminiprid, may transfer to fetuses at a high rate. The oral median lethal dose (LD₅₀) of DMAP is 1,843 mg/kg in female rats [31]. DMAP is the most frequently detected neonicotinoid metabolite in the general Japanese population by ppb level [42], and Marfo et al. reported that DMAP is often detected in patients with symptoms of recent memory loss and finger tremor [34].

DMAP might be transferred via the placenta and accumulate in the fetus, because it was frequently detected in urine collected on PND 1–2 and the level did not increase significantly on PND 14. Acetaminiprid is rapidly metabolized to DMAP after oral administration in healthy

male adults [42]. Its urinary excretion half-life is 1.65 days [38]. Continuous maternal intake of acetamiprid may cause high DMAP levels in maternal blood and DMAP contamination in the fetus. There are two possible reasons why DMAP was detected at a higher rate in SGA infants. First, body composition differs between SGA and AGA infants: % body fat is lower in SGA infants and the brain volume is relatively large. Assuming that DMAP accumulates via nAChRs in the brain, more neonicotinoids may accumulate in SGA infants. A second reason is that DMAP might inhibit growth by affecting neurological development of the fetus.

The parent compound of DMAP, acetamiprid, is a common neonicotinoid in Japan that is used for a wide range of plant protection, including fruits, vegetables, tea leaves, rice paddies, turf, ornamental flowers, and pine trees. The oral LD₅₀ of acetamiprid is 146 mg/kg in female rats [31]. Fatal cases of human acute intoxication have also been reported [36]. In acute intoxication by acetamiprid, nicotinic symptoms including neuronal symptoms are observed [37]. Acetamiprid has some lipophilicity (Log P_{ow} is 0.8) and is not ionized at physiological pH [31], which suggests that it may be retained in the human body, even if its receptor action is weak. There is also some evidence to suggest that acetamiprid is toxic for neurological development [27, 59–61]. It has yet to be clarified whether neonicotinoids have neurological toxicity in infants, but the safety of acetamiprid should be reviewed based on the possibility that neonicotinoids may transfer to and accumulate in fetuses at a high rate.

The limitations of this study include the small number of subjects, investigation in one region in Japan, the inclusion of VLBW infants born prematurely rather than term newborns, and the lack of examination of pesticides other than neonicotinoids. However, it is likely that exposure to neonicotinoids observed in infants born prematurely will be similar in term newborns because they experience a similar period of exposure. Further studies are needed in a larger number of subjects in various regions, but similar results are likely because the use and environmental detection rates of neonicotinoids have increased worldwide.

Conclusion

This report provides the first evidence worldwide showing that *N*-desmethylacetamiprid (DMAP), a metabolite of acetamiprid, can be transferred to fetuses. DMAP levels were also significantly higher in SGA infants than in AGA infants. The fetal and neonatal periods are extremely important for neurological development, and further studies are needed with regard to the safety of acetamiprid due to transfer and accumulation of its metabolite in the womb.

Acknowledgments

Technical support was provided by Mio Yagihashi, Nagisa Hirano and Hazuki Mizukawa. We also thank Anton Safer for critical reading of this manuscript.

Author Contributions

Conceptualization: Go Ichikawa.

Data curation: Yoshinori Ikenaka.

Formal analysis: Go Ichikawa, Yoshinori Ikenaka.

Funding acquisition: Yoshinori Ikenaka, Mayumi Ishizuka, Kumiko Taira.

Investigation: Go Ichikawa.

Methodology: Takahiro Ichise, Shouta M. M. Nakayama.

Project administration: Go Ichikawa.

Resources: Ryota Kuribayashi.

Supervision: Kumiko Taira, Toshimi Sairenchi, Gen Kobashi, Shigemi Yoshihara.

Visualization: Go Ichikawa.

Writing – original draft: Go Ichikawa.

Writing – review & editing: Yoshinori Ikenaka, Kumiko Taira, Kazutoshi Fujioka, Jean-Marc Bonmatin.

References

1. Simon-Delso N, Amaral-Rogers V, Belzunces LP, Bonmatin JM, Chagnon M, Downs C, et al. Systemic insecticides (neonicotinoids and fipronil): trends, uses, mode of action and metabolites. *Environ Sci Pollut Res Int*. 2015; 22:5–34. <https://doi.org/10.1007/s11356-014-3470-y> PMID: 25233913
2. IRAC International MoA Working Group. IRAC Mode of Action Classification Scheme, issued July 2017, <http://www.iraac-online.org/documents/moa-classification/?ext=pdf>
3. Jeschke P, Nauen R, Schindler M, Elbert A. Overview of the status and global strategy for neonicotinoids. *J Agric Food Chem*. 2011; 59:2897–2908. <https://doi.org/10.1021/jf101303g> PMID: 20565065
4. Tapparo A, Marton D, Giorio C, et al. Assessment of the environmental exposure of honeybees to particulate matter containing neonicotinoid insecticides coming from corn coated seeds. *Environ Sci Technol*. 2012; 46:2592–2599. <https://doi.org/10.1021/es2035152> PMID: 22292570
5. Taira K. Human neonicotinoids exposure in Japan. *Jpn J Clin Ecol*. 2014; 23:1.
6. Plant Products Safety Division & Plant Protection Division, Food Safety and Consumer Affairs Bureau, Ministry of Agriculture, Forestry and Fisheries. Noyaku Yoran 2009. Tokyo: Japan Plant Protection Association. 2010.
7. Incorporated Administrative Agency Food and Agricultural Materials Inspection Center (FAMIC), List of Active Ingredients, <http://www.acis.famic.go.jp/eng/indexeng.htm>
8. Giorio C, Safer A, Sánchez-Bayo F, et al.: An update of the Worldwide Integrated Assessment (WIA) on systemic insecticides. Part 1: new molecules, metabolism, fate, and transport. *Environ Sci Pollut Res*. 2017 Nov 5. <https://doi.org/10.1007/s11356-017-0394-3> PMID: 29105037
9. Hassani AK, Dacher M, Gary V, Lambin M, Gauthier M, Armengaud C. Effects of sublethal doses of acetamiprid and thiamethoxam on the behavior of the honeybee (*Apis mellifera*). *Arch Environ Contam Toxicol*. 2008; 54:653–661. <https://doi.org/10.1007/s00244-007-9071-8> PMID: 18026773
10. Mommaerts V, Reynders S, Boulet J, Besard L, Sterk G, Smagge G. Risk assessment for side-effects of neonicotinoids against bumblebees with and without impairing foraging behavior. *Ecotoxicology*. 2010; 19:207–215. <https://doi.org/10.1007/s10646-009-0406-2> PMID: 19757031
11. Van Dijk TC, Van Staalduinen MA, Van der Sluijs JP. Macro-invertebrate decline in surface water polluted with imidacloprid. Desneux N, ed. *PLoS One*. 2013; 8:e62374. <https://doi.org/10.1371/journal.pone.0062374> PMID: 23650513
12. Chagnon M, Kreutzweiser D, Mitchell EAD, Morrissey CA, Noome DA, Van der Sluijs JP. Risks of large-scale use of systemic insecticides to ecosystem functioning and services. *Environ Sci Pollut Res*. 2015; 22:119–134. <https://doi.org/10.1007/s11356-014-3277-x> PMID: 25035052
13. Pisa L, Goulson D, Yang EC, Gibbons D, Sánchez-Bayo F, Mitchell E, et al. An update of the Worldwide Integrated Assessment (WIA) on systemic insecticides. Part 2: impacts on organisms and ecosystems. *Environ Sci Pollut Res*. 2017 Nov 9. <https://doi.org/10.1007/s11356-017-0341-3> PMID: 29124633
14. European Commission. Commission implementing regulation (EU) No 485/2013 of 24 May 2013. *Official Journal of the European Union* 2013; L139/12-26.
15. European decision 2018 with application 2019: imidacloprid <https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32018R0783&from=EN>
16. European decision 2018 with application 2019: clothianidin <https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32018R0784&from=EN>
17. European decision 2018 with application 2019: thiamethoxam <https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32018R0785&from=EN>
18. French law (voted 2016 with application 2018 for a total ban of all neonics): <http://www.assemblee-nationale.fr/14/amendements/3833/AN/452.asp>

19. Cimino AM, Boyles AL, Thayer KA, Perry MJ. Effects of neonicotinoid pesticide exposure on human health: a systematic review. *Environ Health Perspect*. 2017; 125:155–162. <https://doi.org/10.1289/EHP515> PMID: 27385285
20. Hallmann CA, Foppen RPB, van Turnhout CAM, de Kroon H, Jongejans E. Declines in insectivorous birds are associated with high neonicotinoid concentrations. *Nature*. 2014; 511:341–343. <https://doi.org/10.1038/nature13531> PMID: 25030173
21. Hsiao CJ, Lina CL, Lin TY, Wang SE, Wu CH. Imidacloprid toxicity impairs spatial memory of echolocation bats through neural apoptosis in hippocampal CA1 and medial entorhinal cortex areas. *Neuroreport* 2016; 27:462–468. <https://doi.org/10.1097/WNR.0000000000000562> PMID: 26966783
22. Berheim EH, Jenks JA, Lundgren JG, Michel ES, Grove D, Jensen WF. Effects of neonicotinoid insecticides on physiology and reproductive characteristics of captive female and fawn white-tailed deer. *Sci Rep*. 2019; 9:4534. <https://doi.org/10.1038/s41598-019-40994-9> PMID: 30872713
23. Kawahata I, Yamakuni T. Imidacloprid, a neonicotinoid insecticide, facilitates tyrosine hydroxylase transcription and phenylethanolamine N-methyltransferase mRNA expression to enhance catecholamine synthesis and its nicotine-evoked elevation in PC12D cells. *Toxicology* 2018; 394:84–92. <https://doi.org/10.1016/j.tox.2017.12.004> PMID: 29246838
24. Di Prisco G, Iannaccone M, Ianniello F, Ferrara R, Caprio E, Pennacchio F, et al. The neonicotinoid insecticide clothianidin adversely affects immune signaling in a human cell line. *Sci Rep*. 2017; 7:13446. <https://doi.org/10.1038/s41598-017-13171-z> PMID: 29044138
25. Caron-Beaudoin E, Viau R, Sanderson JT. Effects of neonicotinoid pesticides on promoter-specific aromatase (CYP19) expression in Hs578t breast cancer cells and the role of the VEGF Pathway. *Environ Health Perspect*. 2018; 126:047014. <https://doi.org/10.1289/EHP2698> PMID: 29701941
26. Wang X, Anadon A, Wu Q, Qiao F, Martinez-Larranaga MR, Yuan Z, et al. Mechanism of neonicotinoid toxicity: impact on oxidative stress and metabolism. *Annu Rev Pharmacol Toxicol*. 2018; 58:471–507. <https://doi.org/10.1146/annurev-pharmtox-010617-052429> PMID: 28968193
27. Sano K, Isobe T, Yang J, Win-Shwe TT, Yoshikane M, Nakayama SF, et al. In utero and lactational exposure to acetamiprid induces abnormalities in socio-sexual and anxiety-related behaviors of male mice. *Front Neurosci*. 2016; 10:228. <https://doi.org/10.3389/fnins.2016.00228> PMID: 27375407
28. Hirano T, Yanai S, Takada T, Yoneda N, Omotehara T, Kubota N, et al. NOAEL-dose of a neonicotinoid pesticide, clothianidin, acutely induce anxiety-related behavior with human-audible vocalizations in male mice in a novel environment. *Toxicol Lett*. 2018; 282:57–63. <https://doi.org/10.1016/j.toxlet.2017.10.010> PMID: 29030271
29. Burke AP, Niibori Y, Terayama H, Ito M, Pidgeon C, Arsenault J, et al. Mammalian susceptibility to a neonicotinoid insecticide after fetal and early postnatal exposure. *Sci Rep*. 2018; 8:16639. <https://doi.org/10.1038/s41598-018-35129-5> PMID: 30413779
30. Food Safety Commission of Japan. Risk assessment reports: Imidacloprid. <http://www.fsc.go.jp/fscis/evaluationDocument/show/kya20100125001>.
31. Food Safety Commission of Japan. Risk assessment reports: Acetamiprid. <http://www.fsc.go.jp/fscis/evaluationDocument/show/kya20140702188>.
32. Food Safety Commission of Japan. Risk assessment reports: Clothianidin. <http://www.fsc.go.jp/fscis/evaluationDocument/show/kya20140407127>.
33. Taira K, Fujioka K, Aoyama Y. Qualitative profiling and quantification of neonicotinoid metabolites in human urine by liquid chromatography coupled with mass spectrometry. *PLoS One*. 2013; 8:e80332. <https://doi.org/10.1371/journal.pone.0080332> PMID: 24265808
34. Marfo JT, Fujioka K, Ikenaka Y, Nakayama SM, Mizukawa H, Aoyama Y, et al. Relationship between urinary N-desmethyl-acetamiprid and typical symptoms including neurological findings: a prevalence case-control study. *PLoS One*. 2015; 10:e0142172. <https://doi.org/10.1371/journal.pone.0142172> PMID: 26535579
35. Lin PC, Lin HJ, Liao YY, Guo HR, Chen KT. Acute poisoning with neonicotinoid insecticides: a case report and literature review. *Basic Clin Pharmacol Toxicol*. 2013; 112:282–286. <https://doi.org/10.1111/bcpt.12027> PMID: 23078648.
36. Yeter O, Aydin A. Determination of acetamiprid and IM-1-2 in postmortem human blood, liver, stomach contents by HPLC-DAD. *J Forensic Sci*. 2014; 59:287–292. <https://doi.org/10.1111/1556-4029.12368> PMID: 24329162
37. Imamura T, Yanagawa Y, Nishikawa K, Matsumoto N. Two cases of acute poisoning with acetamiprid in humans. *Clin Toxicol*. 2010; 48:851–853.
38. Vinod KV, Srikant S, Thiruvikramaprakash G, Dutta TK. A fatal case of thiacloprid poisoning. *Am J Emerg Med*. 2015; 33:310.e5–6. <https://doi.org/10.1016/j.ajem.2014.08.013> PMID: 25200504

39. Zuercher P, Gerber D, Schai N, Nebiker M, König S, Schefold JC. Calypso's spell: accidental near-fatal thiacloprid intoxication. *Clin Case Rep*. 2017; 5;1672–1675. <https://doi.org/10.1002/ccr3.1146> PMID: 29026570
40. Brunet JL, Maresca M, Fantini J, Belzunces LP. Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model. *Toxicol Appl Pharmacol*. 2004; 194:1–9. <https://doi.org/10.1016/j.taap.2003.08.018> PMID: 14728974
41. Brunet JL, Maresca M, Fantini J, Belzunces LP. Intestinal absorption of the acetamiprid neonicotinoid by Caco-2 cells: transepithelial transport, cellular uptake and efflux. *J Environ Sci Health B*. 2008; 43:261–270. <https://doi.org/10.1080/03601230701771446> PMID: 18368547
42. Harada KH, Tanaka K, Sakamoto H, Imanaka M, Niisoe T, Hitomi T, et al. Biological monitoring of human exposure to neonicotinoids using urine samples, and neonicotinoid excretion kinetics. *PLoS One*. 2016; 11:e0146335. <https://doi.org/10.1371/journal.pone.0146335> PMID: 26731104
43. Fuke C, Nagai T, Ninomiya K, Fukasawa M, Ihama Y, Miyazaki T. Detection of imidacloprid in biological fluids in a case of fatal insecticide intoxication. *Legal Med* 2014; 16:40–43. [dx.doi.org/10.1016/j.legalmed.2013.10.007](https://doi.org/10.1016/j.legalmed.2013.10.007) PMID: 24275505
44. Tomizawa M, Casida JE. Imidacloprid, thiacloprid, and their imine derivatives up-regulate the 42 nicotinic acetylcholine receptor in M10 cells. *Toxicol Appl Pharmacol*. 2000; 169:114–120. <https://doi.org/10.1006/taap.2000.9057> PMID: 11076703
45. Ikenaka Y, Miyabara Y, Ichise T, Nakayama S, Nimako C, Ishizuka M, et al. Exposures of children to neonicotinoids in pine wilt disease control areas. *Environ Toxicol Chem*. 2019; 38:71–79. <https://doi.org/10.1002/etc.4316> PMID: 30478955
46. European Food Safety Authority. The 2013 European Union report on pesticide residues in food. *EFSA Journal* 2015; 13(3):4038
47. Craddock HA, Huang D, Turner PC, Quirós-Alcalá L, Payne-Sturges DC. Trends in neonicotinoid pesticide residues in food and water in the United States, 1999–2015. *Environ Health*. 2019; 18:7. <https://doi.org/10.1186/s12940-018-0441-7> PMID: 30634980
48. Wong KKK, Webb DT, Nagorzanski MR, Kolpin DW, Hladik ML, Cwiertny DM, et al. Chlorinated byproducts of neonicotinoids and their metabolites: an unrecognized human exposure potential? *Environ Sci Technol Lett*. 2019; 6:98–105. <https://doi.org/10.1021/acs.estlett.8b00706>
49. Ueyama J, Harada KH, Koizumi A, Sugiura Y, Kondo T, Saito I, et al. Temporal levels of urinary neonicotinoid and dialkylphosphate concentrations in Japanese women between 1994 and 2011. *Environ Sci Technol*. 2015; 49:14522–14528. <https://doi.org/10.1021/acs.est.5b03062> PMID: 26556224
50. Osaka A, Ueyama J, Kondo T, Nomura H, Sugiura Y, Saito I, et al. Exposure characterization of three major insecticide lines in urine of young children in Japan: neonicotinoids, organophosphates, and pyrethroids. *Environ Res*. 2016; 147:89–96. <https://doi.org/10.1016/j.envres.2016.01.028> PMID: 26855126
51. Kavvalakis MP, Tzatzarakis MN, Theodoropoulou EP, Barbounis EG, Tsakalof AK, Tsatsakis AM. Development and application of LC-APCI-MS method for biomonitoring of animal and human exposure to imidacloprid. *Chemosphere* 2013; 93:2612–2620. <https://doi.org/10.1016/j.chemosphere.2013.09.087> PMID: 24344394
52. Lehmann E, Oltramare C, Nfon Dibié JJ, Konaté Y, de Alencastro LF. Assessment of human exposure to pesticides by hair analysis: The case of vegetable-producing areas in Burkina Faso. *Environ Int*. 2018; 111:317–331. <https://doi.org/10.1016/j.envint.2017.10.025> PMID: 29128258
53. Liang FW, Chou HC, Chiou ST, Chen LH, Wu MH, Lue HC, et al. Trends in birth weight-specific and -adjusted infant mortality rates in Taiwan between 2004 and 2011. *Pediatr Neonatol*. 2017. <https://doi.org/10.1016/j.pedneo.2017.08.013> PMID: 28965850
54. Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. *Clin Med Insights Pediatr*. 2016; 10:67–83. <https://doi.org/10.4137/CMPed.S40070> PMID: 27441006
55. Saunders NR, Liddelow SA, Dziegielewska KM. Barrier mechanisms in the developing brain. *Front Pharmacol*. 2012; 3:46. <https://doi.org/10.3389/fphar.2012.00046> PMID: 22479246
56. Ek CJ, Dziegielewska KM, Habgood MD, Saunders NR. Barriers in the developing brain and neurotoxicology. *Neurotoxicology*. 2012; 33:586–604. <https://doi.org/10.1016/j.neuro.2011.12.009> PMID: 22198708
57. Ministry of Health Labour and Welfare. Specified Report of Vital Statistics. Tokyo: Vital, Health and Social Statistics Office; 2010.
58. Puga B, Puga PG, de Arriba A, Armendariz Y, Labarta JI, Longas AF. Psychomotor and intellectual development (neurocognitive function) of children born small for gestational age (SGA). Transversal and longitudinal study. *Pediatr Endocrinol Rev*. 2009; 6 Suppl 3:358–370.
59. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional

Study of the INTERGROWTH-21st Project. *Lancet* 2014; 384:857–868. [https://doi.org/10.1016/S0140-6736\(14\)60932-6](https://doi.org/10.1016/S0140-6736(14)60932-6) PMID: 25209487

60. Kimura-Kuroda J, Komuta Y, Kuroda Y, Hayashi M, Kawano H. Nicotine-like effects of the neonicotinoid insecticides acetamiprid and imidacloprid on cerebellar neurons from neonatal rats. *PLoS One*. 2012; 7: e32432. <https://doi.org/10.1371/journal.pone.0032432> PMID: 22393406
61. Kimura-Kuroda J, Nishito Y, Yanagisawa H, Kuroda Y, Komuta Y, Kawano H, et al. Neonicotinoid insecticides alter the gene expression profile of neuron-enriched cultures from neonatal rat cerebellum. *Int J Environ Res Public Health*. 2016; 13.